COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected an estimated 251 million people with over 5 million deaths. Despite COVID-19 starting as a respiratory disease, several neurologic symptoms associated to the disease have been reported. Some of these symptoms are mild and non-life threatening (e.g., anosmia, headache, dizziness, etc.), however, there are some other which are critical and life threatening (e.g., stroke or seizure). Furthermore, many of these symptoms can remain for a long time after the acute illness has passed, a phenomenon known as post-acute sequelae of SARS-CoV-2 infection (PASC), which can also lead to the development of neurological diseases such as encephalitis, encephalopathy, and meningitis.
So far, the molecular and cellular mechanisms underlying these effects have not yet been elucidated, and therefore, the therapeutic options to treat the neurological sequelae of COVID-19 are still scarce and ineffective.
The increasing evidence of SARS-CoV-2 impact on the central nervous system (CNS) raises some questions on its impact for risk. Therefore, it is important to achieve a better understanding of the cellular and molecular mechanisms that lead to short and long-term neurological COVID-19 sequelae, which can even conduct to development and/or progression of neurological diseases.
This Research Topic focused on Short and long-term sequelae within the CNS due to COVID-19 is intended to provide a comprehensive overview of the neuroinvasion mechanisms of SARS-CoV-2, the pathophysiology of COVID-19-related neurological implications and the possible therapeutic approaches. In that sense, we seek Original Research, Review, Mini-Review, Hypothesis and Theory, Perspective, Clinical Trial, Case Report and Opinion articles that cover, but are not limited to, the following topics:
• Biomarkers in the assessment of CNS manifestations of COVID-19.
• Molecular and cellular mechanisms that underlay short and long-term implications of COVID-19 infection.
• Neuroinvasion mechanisms of SARS-CoV-2
• Pathophysiology of COVID-19-related neurological implications.
• Potential therapy for COVID-19-related neurological sequelae.
COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected an estimated 251 million people with over 5 million deaths. Despite COVID-19 starting as a respiratory disease, several neurologic symptoms associated to the disease have been reported. Some of these symptoms are mild and non-life threatening (e.g., anosmia, headache, dizziness, etc.), however, there are some other which are critical and life threatening (e.g., stroke or seizure). Furthermore, many of these symptoms can remain for a long time after the acute illness has passed, a phenomenon known as post-acute sequelae of SARS-CoV-2 infection (PASC), which can also lead to the development of neurological diseases such as encephalitis, encephalopathy, and meningitis.
So far, the molecular and cellular mechanisms underlying these effects have not yet been elucidated, and therefore, the therapeutic options to treat the neurological sequelae of COVID-19 are still scarce and ineffective.
The increasing evidence of SARS-CoV-2 impact on the central nervous system (CNS) raises some questions on its impact for risk. Therefore, it is important to achieve a better understanding of the cellular and molecular mechanisms that lead to short and long-term neurological COVID-19 sequelae, which can even conduct to development and/or progression of neurological diseases.
This Research Topic focused on Short and long-term sequelae within the CNS due to COVID-19 is intended to provide a comprehensive overview of the neuroinvasion mechanisms of SARS-CoV-2, the pathophysiology of COVID-19-related neurological implications and the possible therapeutic approaches. In that sense, we seek Original Research, Review, Mini-Review, Hypothesis and Theory, Perspective, Clinical Trial, Case Report and Opinion articles that cover, but are not limited to, the following topics:
• Biomarkers in the assessment of CNS manifestations of COVID-19.
• Molecular and cellular mechanisms that underlay short and long-term implications of COVID-19 infection.
• Neuroinvasion mechanisms of SARS-CoV-2
• Pathophysiology of COVID-19-related neurological implications.
• Potential therapy for COVID-19-related neurological sequelae.
